Three‐month formulation of paliperidone delays relapse in schizophrenia

By  

THE BROWN UNIVERSITY PSYCHOPHARMACOLOGY UPDATE, Vol. 26, Iss. 7, 2015-07 ,pp. : 3-4

John Wiley & Sons Inc

Access to resources Recommend Favorite

Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia

By Järbrink Krister   Kreif Noemi   Benedict Agnes   Locklear Julie  

Current Medical Research and Opinion, Vol. 25, Iss. 3, 2009-03 ,pp. : 709-716

Informa Healthcare

Access to resources Recommend Favorite

Assessing the Value-Adding Impact of Diagnostic-Type Tests on Drug Development and Marketing

By Blair Edward D.  

Molecular Diagnosis & Therapy, Vol. 12, Iss. 5, 2008-01 ,pp. : 331-337

Adis International

Access to resources Recommend Favorite

Assessing the impact of patient self‐selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin

By  

JOURNAL OF EVALUATION IN CLINICAL PRACTICE (ELECTRONIC), Vol. 20, Iss. 5, 2014-10 ,pp. : 685-691

John Wiley & Sons Inc

Access to resources Recommend Favorite

Population pharmacokinetic modeling of quetiapine after administration of seroquel and seroquel XR formulations to Western and Chinese patients with schizophrenia, schizoaffective disorder, or bipolar disorder

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 91-2700, Iss. 11, 2015-11 ,pp. : 1248-1255

John Wiley & Sons Inc

Access to resources Recommend Favorite